complex
clinic
pictur
viru
infect
foetu
process
organogenesi
first
month
pregnanc
extrem
like
infant
born
gross
defect
nevertheless
infant
escap
development
defect
show
sign
infect
low
birth
weight
hepatosplenomegali
viru
often
persist
foetal
tissu
throughout
gestat
recov
infant
birth
menser
et
al
monif
et
al
latter
group
viru
easili
isol
throat
csf
urin
faec
liver
month
birth
rubella
syndrom
children
therefor
import
infecti
sourc
pregnant
women
prospect
studi
establish
mother
infect
first
week
pregnanc
minim
figur
infant
congenit
defect
author
would
suggest
higher
figur
approach
incid
congenit
defect
princip
deaf
result
intrauterin
infect
first
month
pregnanc
estim
review
banatvala
best
also
rememb
rubella
infect
mother
may
result
spontan
abort
case
usual
infect
occur
first
eight
week
rubella
viru
positivestrand
rna
viru
nm
diamet
lipoprotein
envelop
classifi
nonarthropodborn
togaviru
place
genu
rubiviru
antigen
relationship
shown
exampl
rubella
alpha
flavivirus
cross
reaction
detect
pestivirus
equin
arter
viru
brinton
nucleocapsid
nm
diamet
contain
singl
molecul
rna
infecti
extract
appropri
condit
viral
envelop
acquir
bud
host
cell
pleomorph
charact
viru
particl
presum
due
nonrigid
charact
lipid
envelop
ellipt
oblong
viru
particl
particl
bear
fingerlik
protrus
describ
fig
envelop
bear
poorli
defin
nm
surfac
spike
presum
compos
viral
glycoprotein
carri
phdepend
ha
activ
least
four
see
major
polypeptid
describ
three
glycoprotein
associ
envelop
e
nonglycosyl
core
protein
c
may
repres
viral
structur
protein
precursor
polypeptid
host
protein
remain
associ
purifi
viru
okerblom
et
al
alstyn
et
al
tabl
three
glycoprotein
approxim
molecular
weight
respect
whilst
molecular
weight
c
protein
would
impli
structur
gene
code
capac
subgenom
rna
speci
detect
viru
infect
cell
okerblom
et
al
thu
rubella
may
similar
regard
alphavirus
mrna
encod
precursor
structur
protein
quit
like
three
gene
requir
code
viru
protein
sinc
similar
tryptic
map
attack
usual
mild
character
day
rash
swollen
perhap
slightli
tender
lymph
node
slight
temperatur
rise
scarc
notic
malais
christi
summar
trifl
ailment
caus
less
inconveni
patient
common
cold
mani
case
rash
appar
subclin
infect
proce
silent
regardless
sever
rubella
adult
foetu
infect
result
congenit
infect
incub
period
rubella
day
rash
first
appear
face
around
mouth
behind
ear
trunk
spot
first
discret
size
pin
head
rash
progress
spread
rapidli
cover
arm
leg
well
anoth
tendenc
rubella
rash
come
go
hour
person
infecti
day
rash
appear
transmiss
viru
aerosol
inhal
upper
respiratori
tract
common
complic
rubella
adult
arthriti
arthralgia
fig
electron
micrograph
rubella
viru
kindli
suppli
dr
chrysti
st
thoma
hospit
patient
may
persist
week
commonli
smaller
joint
involv
central
nervou
system
complic
rare
follow
rubella
enceph
incid
rate
approxim
gener
assum
onset
enceph
usual
sudden
within
day
two
rash
symptom
may
vari
headach
drowsi
convuls
coma
import
aspect
rubella
prevent
congenit
infect
seem
achiev
goal
follow
introduct
sever
live
attenu
vaccin
time
usa
alon
estim
x
case
rubella
occur
malform
infant
instanc
foetal
wastag
review
hinman
et
al
fig
howev
nearli
two
decad
later
enthusiast
high
expect
earli
day
meyer
et
al
weibel
et
al
achiev
least
mani
countri
review
banatvala
clark
et
grenstein
grear
reflect
lack
efficaci
vaccin
rather
critic
nation
health
author
gener
somnol
extent
scientif
disagr
best
use
vaccin
follow
isol
cultiv
rubella
viru
tissu
cultur
earli
parkman
et
al
weller
neva
mccarthi
et
al
rapid
progress
made
develop
number
simpl
attenu
vaccin
exampl
viru
passag
time
vervet
monkey
kidney
cell
vaccin
time
duck
embryo
fibroblast
found
attenu
success
children
adult
buynack
et
al
anoth
strain
viru
passag
time
primari
rabbit
kidney
cell
cendehil
vaccin
huygelen
peeterman
zygraich
et
al
whilst
third
viru
passag
time
hek
time
human
diploid
cell
ra
plotkin
et
al
final
recent
japanes
vaccin
viru
passag
vervet
mk
cell
tabl
time
time
primari
guinea
pig
kidney
cell
best
et
al
vaccin
administ
produc
seroconvers
suscept
person
limit
side
effect
nevertheless
experi
indic
dk
vaccin
produc
unaccept
side
effect
arthralgia
arthriti
withdrawn
usa
exampl
later
hpv
vaccin
also
withdrawn
replac
vaccin
meruvax
side
effect
includ
arthriti
arthralgia
usual
mild
best
et
al
earli
studi
show
vaccin
virus
transmit
potenti
suscept
sentinel
volunt
halstead
diwan
l
essenti
requir
known
first
whether
vaccin
virus
teratogen
immun
induc
long
live
hoshino
et
al
fig
experi
last
year
shown
rubella
vaccin
virus
teratogen
activ
although
isol
foetal
tissu
infant
whose
mother
inadvert
vaccin
pregnanc
modlin
et
al
experi
accumul
differ
rubella
vaccin
becom
clearer
side
effect
associ
longev
immun
respons
induc
might
also
differ
short
would
appear
rubella
vaccin
strain
posit
featur
virus
rubella
hi
antibodi
titr
month
vaccin
weibel
et
al
current
use
rather
wide
scale
immun
induc
close
resembl
immun
respons
natur
acquir
infect
particular
viru
first
isol
explant
surgic
abort
foetu
direct
inocul
human
diploid
fibroblast
review
plotkin
et
viru
attenu
low
temperatur
passag
clone
cell
use
immun
passag
cell
dose
tcidso
administ
intranas
sc
inject
latter
techniqu
favour
eight
compar
studi
perform
differ
countri
mean
hi
antibodi
titr
immun
either
rout
higher
vaccin
compar
cendehil
vaccin
plotkin
et
al
similarli
higher
level
neutral
antibodi
detect
follow
cendehil
vaccin
tabl
higher
level
c
f
antibodi
de
vaccin
tabl
nasal
antibodi
rubella
specif
iga
regularli
detect
intranas
vaccin
frequent
detect
sc
inject
vaccin
contrast
although
specif
iga
antibodi
detect
cendehil
vaccin
exampl
persist
well
best
et
al
tabl
note
evid
transmiss
person
infect
intranas
vaccin
import
aspect
rubella
vaccin
whether
recipi
could
becom
reinfect
later
date
wild
rubella
viru
could
still
produc
teratogen
effect
earli
studi
person
receiv
cendehil
vaccin
expos
wild
viru
natur
artifici
vaccin
reinfect
rate
rang
tabl
vaccine
reinfect
rate
observ
close
figur
obtain
follow
natur
infect
recent
studi
best
person
commun
challeng
number
per
son
vaccin
year
earlier
viraemia
detect
vaccine
antibodi
level
intern
unit
therefor
yet
known
whether
adequ
level
antibodi
persist
vaccine
year
vaccin
exampl
summari
number
success
rubella
vaccin
develop
empir
without
knowledg
genet
viru
molecular
basi
virul
attenu
perhap
absenc
precis
virolog
knowledg
taken
year
field
trial
establish
variou
vaccin
strain
ident
vari
exampl
abil
produc
long
live
immun
respons
side
effect
vaccin
strain
would
appear
success
one
particular
interest
though
analyz
genom
differ
virus
henc
determin
exampl
mani
mutat
requir
chang
rubella
strain
virul
one
attenu
one
could
lead
artifici
construct
new
gener
attenu
vaccin
see
chapter
rubella
vaccin
gener
well
toler
lymphadenopathi
rash
arthralgia
arthriti
may
occur
two
four
week
vaccin
although
reaction
usual
less
sever
follow
natur
acquir
diseas
review
banatvala
best
best
et
al
studi
seroneg
volunt
given
cendehil
japanes
vaccin
joint
symptom
detect
vaccine
best
et
al
persist
eight
day
tabl
vaccin
licens
two
strategi
use
discuss
singl
aim
name
prevent
congenit
rubella
syndrom
rs
widespread
vaccin
adolesc
girl
women
would
prevent
rs
would
influenc
viru
transmiss
commun
hand
routin
vaccin
children
boy
girl
earli
life
would
increas
herd
immun
interrupt
transmiss
diseas
usa
adopt
latter
polici
whilst
uk
symptom
last
seven
day
adopt
former
polici
recent
epidemiolog
model
studi
shown
countri
taken
correct
decis
fraction
suscept
vaccin
less
better
let
natur
rubella
spread
eg
uk
wherea
countri
high
rate
immun
like
achiev
eg
usa
polici
erad
follow
vaccin
given
boy
girl
hinman
et
al
anderson
may
fact
latter
assess
perhap
rather
diplomat
sever
critic
would
pronounc
whilst
usa
polici
least
prevent
extens
outbreak
reduc
rs
uk
polici
present
time
done
neither
summari
usa
experi
schiff
shown
follow
incid
rs
decreas
significantli
fig
vaccin
virus
teratogen
vaccin
choic
may
ra
herd
immun
stop
outbreak
outbreak
occur
unvaccin
group
eg
young
adult
year
old
femal
remain
suscept
much
vigor
campaign
therefor
requir
even
usa
immun
suscept
women
child
bear
age
also
rais
immun
level
school
children
sabin
take
rather
individu
viewpoint
queri
whether
fact
small
number
rs
case
justifi
larg
scale
immun
programm
case
specul
mass
immun
campaign
shorf
period
time
would
necessari
break
chain
viru
transmiss
similarli
measl
sinc
rubella
vaccin
live
viru
vaccin
given
patient
whose
immun
defici
whether
result
diseas
eg
malign
treatment
corticosteroid
radiotherapi
cytotox
drug
sinc
rubella
vaccin
may
transmit
transplacent
pregnanc
contraind
avoid
three
month
vaccin
examin
product
concept
rubellasuscept
women
vaccin
inadvert
pregnanc
shown
rubella
viru
may
recov
placenta
kidney
bone
marrow
furthermor
histopatholog
studi
shown
chang
placenta
decidua
foetal
eye
similar
occur
natur
acquir
infect
howev
clinic
serolog
followup
studi
carri
women
usa
elect
go
term
inadvert
rubella
vaccin
earli
pregnanc
shown
none
infant
deliv
mother
known
rubella
suscept
given
rubella
vaccin
within
period
rang
month
month
concept
major
malform
mani
infant
follow
sinc
though
serolog
evid
intrauterin
infect
none
defect
compat
congenit
rubella
risk
rubellainduc
major
malform
among
infant
deliv
suscept
mother
calcul
base
confid
limit
figur
similar
risk
normal
pregnanc
tabl
unit
state
immunis
practic
advisori
committe
still
recommend
pregnant
women
given
rubella
vaccin
state
inadvert
vaccin
longer
reason
recommend
termin
pregnanc
routin
result
serolog
survey
uk
indic
rubella
vaccin
programm
impact
serolog
statu
young
adult
femal
studi
popul
clear
fig
women
elig
vaccin
school
proport
seroneg
much
lower
men
age
older
women
low
frequenc
seroneg
subject
among
women
born
found
consist
throughout
studi
relat
chronolog
expect
effect
vaccin
clark
et
al
first
year
blooddonor
studi
seroneg
proport
women
born
consist
higher
men
age
fig
howev
percentag
seroneg
women
born
lower
men
age
women
born
possibl
explan
find
age
group
includ
mother
vaccin
postnat
clinic
birth
child
indic
persist
rubella
antibodi
vaccin
obtain
result
women
born
would
first
year
studi
vaccin
year
previous
year
previous
assum
differ
proport
seroneg
subject
men
women
born
due
rubella
vaccin
consequ
rapid
fall
antibodi
due
vaccin
would
proport
seroneg
women
would
tend
revert
men
age
evid
occur
thu
appear
period
antibodi
level
persist
year
vaccin
evid
indic
antibodi
persist
major
vaccine
year
vaccin
oshea
et
al
hambl
conduct
studi
uk
serum
sampl
women
childbear
age
test
rubella
antibodi
found
seroneg
proport
among
women
elig
vaccin
school
lower
among
older
women
studi
report
similar
trend
hutchinson
et
al
two
studi
clubb
et
al
gilmour
et
al
fail
find
effect
attribut
vaccin
number
serum
sampl
test
latter
studi
much
lower
studi
survey
shown
frequenc
seroneg
schoolchildren
year
seroneg
young
adult
male
uk
similar
report
introduct
vaccin
find
would
expect
select
natur
vaccin
programm
individu
constitut
suscept
group
could
contribut
spread
rubella
commun
influenc
incid
congenit
rubella
may
discern
futur
experi
uk
compar
usa
sex
vaccin
infanc
hinman
et
al
n
survey
peckham
et
al
old
girl
report
receiv
rubella
vaccin
although
uptak
vari
wide
differ
part
uk
rubella
vaccin
campaign
uptak
vaccin
increas
fell
short
aim
campaign
howev
extens
local
campaign
achiev
uptak
excess
effort
obvious
need
increas
uptak
rubella
vaccin
serolog
survey
certain
adolesc
young
adult
popul
indic
suscept
level
rubella
approxim
percent
see
appreci
differ
report
prevaccin
year
furthermor
adolesc
young
adult
account
high
proport
report
measl
see
chapter
rubella
case
particularli
usa
greatest
risk
diseas
fact
illustr
measl
rubella
outbreak
report
secondari
school
colleg
militari
instal
place
employ
usa
pattern
diseas
transmiss
led
increas
effort
vaccin
older
suscept
person
ideal
need
vaccin
would
identifi
sensit
specif
readili
avail
inexpens
screen
techniqu
provid
immedi
inform
obviou
approach
histori
previou
measl
rubella
infect
vaccin
howev
previou
report
indic
inform
obtain
prospect
vaccine
parent
may
accur
predictor
suscept
preblud
et
al
recent
studi
evalu
sensit
specif
histori
past
infect
vaccin
determin
cost
effect
three
altern
strategi
vaccin
person
suscept
measl
rubella
vaccin
ull
person
regardless
past
histori
serolog
screen
person
vaccin
suscept
vaccin
person
physiciandocu
proof
proper
vaccin
past
infect
measl
serolog
immun
author
found
except
categori
histori
respons
associ
measl
suscept
rate
approxim
less
matern
histori
statist
specif
cadet
histori
p
identifi
two
third
suscept
person
cadet
matern
histori
either
infect
vaccin
sensit
identifi
immun
subject
histori
neither
nonspecif
identifi
suscept
person
posit
histori
previou
rubella
infect
vaccin
associ
lower
suscept
rate
neg
histori
p
howev
histori
success
identifi
person
suscept
rubella
cadet
matern
histori
rubella
vaccin
specif
histori
p
neg
histori
vaccin
still
fail
identifi
approxim
subject
suscept
rubella
comparison
discord
respons
confirm
matern
histori
gener
reliabl
cadet
histori
cost
effect
three
altern
vaccin
strategi
model
cohort
subject
investig
vaccin
person
least
expens
strategi
total
cost
cost
per
suscept
person
protect
unless
record
avail
popul
question
case
vaccin
record
review
less
expens
howev
vaccin
record
review
associ
lower
proport
protect
suscept
person
compar
two
strategi
potenti
vaccine
record
approxim
protect
vs
find
alter
even
one
assum
record
accur
accur
gener
littl
differ
total
cost
administ
either
measl
rubella
vaccin
alon
combin
cost
per
suscept
person
protect
indic
combin
measl
rubella
vaccin
programm
highli
econom
combin
programm
provid
reduct
cost
compar
rubellaonli
vaccin
programm
except
serolog
screeningvaccin
strategi
case
combin
programm
cost
approxim
fourfold
fivefold
reduct
compar
measlesonli
vaccin
programm
prevent
rubella
use
immun
globulin
normal
immun
globulin
may
prolong
incub
period
consider
sinc
inappar
infect
accompani
viraemia
foetal
damag
prevent
forrest
honeyman
polakoff
howev
peckham
show
infant
mother
given
normal
human
immun
globulin
experienc
subclin
rubella
earli
pregnanc
less
like
infect
utero
infant
whose
mother
given
immun
globulin
therefor
possibl
administr
normal
human
globulin
reduc
level
foetal
infect
damag
hightitr
rubella
immun
globulin
use
experiment
determin
whether
infect
induc
rubella
vaccin
prevent
urquhart
et
al
result
encourag
volunt
given
hightitr
immun
globulin
rubella
vaccin
simultan
fail
seroconvert
remain
exhibit
delay
antibodi
respons
compar
volunt
given
vaccin
alon
prepar
short
suppli
avail
via
scottish
blood
transfus
servic
properli
evalu
field
may
recommend
suscept
pregnant
women
come
contact
clinic
rubella
therapeut
abort
unaccept
success
live
attenu
rubella
vaccin
studi
carri
specif
inhibit
rubella
viru
replic
earli
vitro
vivo
work
initi
amantadin
amin
soon
discontinu
rather
low
antivir
efficaci
molecul
investig
thu
oxford
schild
describ
inhibitori
effect
amantadin
microplaqu
format
sever
strain
rubella
viru
fig
tabl
amantadin
pgml
exert
toxic
effect
line
rabbit
kidney
cell
use
wherea
pgml
amantadin
requir
inhibit
microplaqu
format
therapeut
index
therefor
low
particularli
compar
vitro
activ
strain
influenza
viru
see
chapter
amantadin
also
activ
antivir
organ
cultur
ferret
trachea
infect
rubella
viru
strain
fig
antivir
effect
note
prophylact
experi
laboratori
anim
tabl
infect
intranas
rubella
viru
given
rel
high
dosag
compound
mgkg
three
infant
congenit
rubella
syndrom
given
human
leukocyt
al
pha
interferon
dose
x
x
ukg
per
day
day
arvin
et
al
transient
decreas
pharyng
viru
excret
observ
treatment
signific
side
effect
associ
administr
human
leukocyt
interferon
infant
tabl
benefici
effect
note
number
live
attenu
rubella
vaccin
develop
empir
test
last
two
decad
although
efficaci
nevertheless
differ
reactiv
immunogen
detect
rubella
vaccin
design
human
diploid
cell
use
wide
appear
littl
need
chemotherapeut
approach
new
vaccin
rather
intensifi
vaccin
campaign
requir
rubella
epidem
rubella
syndrom
prevent
much
remain
discov
genet
antigen
variat
among
rubella
field
virus
viru
structur
biochemistri
famili
reoviridu
name
reo
aros
respiratori
enter
orphan
consist
reoviru
orbiviru
rotaviru
shown
tabl
virus
famili
seem
infect
human
vertebr
antibodi
found
investig
human
popul
rotavirus
segment
total
molecular
weight
x
fig
show
morpholog
human
rotaviru
particl
lack
envelop
icosahedr
symmetri
made
two
distinct
capsid
shell
outer
shell
remov
chymotrypsin
treatment
reveal
core
core
contain
rna
depend
rna
polymeras
code
viral
genom
poli
polymeras
activ
virion
also
contain
capform
enzym
yamakawa
et
al
viru
particl
bound
receptor
cell
transport
cytoplasm
uncoat
within
lysosom
remov
outer
capsid
proteolyt
enzym
coreassoci
rna
transcriptas
enzym
transcrib
mrna
rna
genom
viru
core
viru
core
also
contain
viral
enzym
necessari
format
cap
viral
mrna
yamakawa
et
al
cap
format
involv
follow
viral
reaction
viral
mrna
contain
polya
sequenc
reoviru
protein
synthes
cleav
cytoplasm
indic
figur
synthesi
minu
strand
form
new
doubl
strand
rna
also
carri
viral
rna
polymeras
cytoplasm
use
replic
complex
consist
one
ten
eleven
plu
strand
rna
molecul
review
see
joklik
detail
knowledg
replic
event
establish
use
reoviru
entir
clear
orbiand
rotavirus
differ
pattern
respect
howev
seem
sever
viral
enzym
reovirida
famili
suitabl
target
antivir
drug
subgroup
sever
common
virus
common
caus
acut
gastroenter
infant
children
respons
half
case
davidson
et
al
symptom
includ
diarrhoea
fever
abdomin
pain
vomit
result
dehydr
sever
especi
third
world
countri
inadequ
medic
care
result
consider
mortal
see
chapter
fig
lob
estim
billion
case
million
childhood
death
occur
year
due
rotavirus
asia
africa
south
america
make
singl
largest
caus
diseas
death
area
world
elliot
kapikian
et
al
gastroenter
caus
rotaviru
also
found
adult
sever
elderli
patient
halvorsrud
orstavik
orbivirus
colorado
tick
fever
caus
mild
human
diseas
fever
faecalor
rout
seem
main
way
transmiss
virus
incub
period
day
incub
period
also
found
volunt
challeng
oral
rotaviru
kapikian
et
al
case
rotaviru
infect
occur
infant
young
children
shown
tabl
season
variat
preval
highest
figur
cold
season
report
sever
studi
middleton
high
frequenc
antibodi
rotaviru
sever
popul
show
common
infect
children
age
two
antibodi
type
type
human
rotaviru
wyatt
et
al
adult
popul
industri
countri
antibodi
rotavirus
gust
et
al
middleton
et
al
use
sensit
elisa
method
determin
presenc
antibodi
rotavirus
figur
seem
approach
differ
popul
ghose
et
al
yolken
et
al
distribut
rotaviru
type
subgroup
present
clear
see
chapter
discuss
molecular
epidemiolog
differ
approach
immun
rotaviru
gastroenter
discuss
reader
refer
excel
review
kapikian
et
al
mclean
holm
saulsburi
et
al
chanock
wyatt
et
al
kapikian
et
al
two
piec
inform
import
context
rotaviru
immun
emphas
one
number
differ
strain
antigen
divers
rel
import
antibodi
serum
intestin
fluid
result
kapikian
et
al
indic
presenc
serum
antibodi
could
prevent
symptomat
infect
challeng
viru
presenc
local
neutral
antibodi
intestin
fluid
shown
davidson
et
al
could
also
import
possibl
use
attenu
live
vaccin
seem
promis
human
type
rotaviru
strain
serial
propag
gnotobiot
piglet
yield
attenu
strain
wa
present
test
safeti
antigen
volunt
edelman
see
chapter
use
live
attenu
bovin
rotaviru
vaccin
vesikari
et
al
recent
achiev
protect
rate
children
rotaviru
epidem
develop
vaccin
hybrid
dna
technolog
use
immunogen
small
polypeptid
certainli
investig
rotaviru
futur
passiv
immun
antibodi
milk
given
infant
also
consid
import
argument
favour
breast
feed
passiv
immun
also
use
immunodefici
patient
chronic
rotaviru
infect
saulsburi
et
al
consid
present
statu
immunotherapi
prophylaxi
rotaviru
kept
mind
virus
known
short
period
time
vaccin
reoor
orbivirus
seem
particularli
import
comparison
great
need
vaccin
rotavirus
especi
underdevelop
countri
clinic
effect
chemotherapi
infect
caus
reoviridu
report
restor
electrolyt
balanc
replac
fluid
oral
parenter
rout
import
case
rotaviru
infect
result
diarrhoea
ribavirin
cell
cultur
inhibit
growth
rotaviru
chang
heel
activ
rotaviru
infect
mice
schoub
prozeski
similar
result
use
ribavirin
compound
cell
cultur
report
smee
et
al
result
shown
tabl
although
antivir
effect
shown
none
compound
ribavirin
monoand
triphosph
effect
rotaviru
rna
polymeras
cellfre
assay
also
compound
show
littl
activ
murin
rotaviru
infect
mice
presenc
sever
viral
enzym
make
feasibl
synthezis
inhibitor
use
anim
model
avail
rotaviru
infect
could
fertil
area
investig
futur
impact
retrovirus
human
diseas
far
clear
involv
sever
anim
tumour
probabl
human
malign
well
implic
aid
retrovirus
divid
three
main
group
shown
tabl
unequivoc
identif
human
retroviru
htlv
see
later
recent
although
group
virus
studi
mani
year
retrovirus
contain
dimer
singlestrand
viral
rna
revers
transcriptas
enzym
envelop
viru
particl
nm
diamet
intern
icosahedr
capsid
contain
rna
monomer
mw
x
viral
protein
glycosyl
envelop
contain
lipid
deriv
plasma
membran
viru
particl
contain
typespecif
groupspecif
antigen
retroviru
replic
start
interact
envelop
glycoprotein
specif
receptor
cellsurfac
uncoat
virion
rna
transcrib
dna
revers
transcriptas
enzym
transfer
rna
function
primer
process
linear
dna
form
contain
termin
repeat
dsdna
circular
retrovir
dna
integr
cellular
dna
way
similar
integr
transposon
integr
seem
requir
viru
replic
integr
viral
dna
transcrib
cellular
rna
polymeras
virion
rna
mrna
viral
genom
contain
gene
group
antigen
gag
revers
transcriptas
pol
envelop
glycoprotein
env
also
onc
sarc
gene
integr
viral
dna
enter
germ
line
transmit
proviru
vertic
manner
retrovirus
associ
anim
leukaemia
lymphoma
sarcoma
carcinoma
human
tcell
leukaemialymphoma
viru
htlv
recent
isol
patient
cutan
tcell
lymphoma
poiesz
et
al
poieszet
miyoshi
et
popovicet
al
reitzet
al
sarin
et
al
integr
htlv
genom
site
cell
patient
matur
tcell
leukaemialymphoma
indic
integr
next
specif
cellular
gene
import
neoplast
transform
hahn
et
al
diseas
aggress
cours
poor
prognosi
skin
manifest
viscer
involv
hypercalcaemia
hepatosplenomegali
lymphadenopathi
virusassoci
malign
show
geograph
cluster
part
usa
caribbean
japan
blattner
et
al
presenc
diseas
clearli
correl
area
htlv
infect
preval
chemotherapi
vaccin
htlv
present
avail
possibl
associ
htlv
case
aid
acquir
immun
defici
syndrom
certainli
arous
consider
addit
interest
essex
et
al
gelman
et
al
barrcsinoussi
et
al
prevent
treatment
infect
malign
caus
htlv
sever
viral
enzym
especi
reversetranscriptas
could
suitabl
target
inhibitor
activ
foscarnet
retrovirus
see
oberg
give
one
exampl
drug
evalu
context
outbreak
gastroenter
winter
vomit
diseas
among
student
teacher
elementari
school
norwalk
ohio
stool
filtrat
secondari
case
abl
subsequ
induc
diseas
volunt
use
immun
electron
microscopi
iem
kapikian
et
identifi
norwalk
agent
nm
viru
particl
sinc
sever
similar
infecti
agent
describ
classif
norwalk
group
virus
uncertain
regard
either
parvoor
calciviru
present
inform
seem
favour
latter
classif
therefor
discuss
mix
bag
chapter
rna
virus
norwalk
group
virus
recent
subject
excel
review
norwalklik
agent
diamet
nm
densiti
csci
possess
one
major
capsid
polypeptid
morpholog
electron
microscopi
similar
picorna
parvoor
calciviru
problem
identif
norwalk
virus
imposs
grow
cell
cultur
overview
possibl
agent
includ
norwalk
viru
group
given
tabl
group
agent
found
em
iem
stool
fig
calcivirus
group
norwalk
viru
might
belong
contain
infecti
singlestrand
rna
mw
x
densiti
csci
diamet
nm
possess
one
major
capsid
polypeptid
diseas
induc
norwalk
viru
mild
selflimit
gastroenter
vomit
diarrhoea
last
day
studi
volunt
incub
time
found
hour
viru
shed
stool
maxim
acut
ill
thornhil
et
al
acut
infect
result
histopatholog
lesion
jejunum
broaden
villi
small
intestin
healthi
adult
preval
antibodi
norwalk
viru
differ
part
world
greenberg
et
al
antibodi
gradual
acquir
period
year
industri
countri
develop
countri
high
preval
antibodi
found
children
acquisit
antibodi
norwalk
viru
take
place
later
rotaviru
black
et
al
contamin
water
seem
often
respons
spread
viru
taylor
et
al
baron
et
al
kaplan
et
al
short
term
immun
observ
volunt
challeng
norwalk
viru
although
immun
prevent
ill
second
challeng
viru
week
later
howev
immun
one
challeng
prevent
ill
rechalleng
delay
month
parrino
et
al
seem
clear
correl
antibodi
level
develop
clinic
symptom
challeng
norwalk
viru
blacklow
et
al
studi
mechan
immun
possibl
influenc
genet
factor
requir
immunoprophylaxi
discuss
specif
antivir
treatment
diseas
present
known
high
incid
acut
gastroenter
caus
rotavirus
call
prophylact
therapeut
measur
although
vaccin
present
avail
seem
like
vaccin
develop
next
year
also
sever
rotaviru
enzym
use
target
antivir
drug
howev
antivir
drug
shown
therapeut
effect
rotaviru
infect
newli
discov
human
retroviru
htlv
yet
investig
detail
predict
use
vaccin
antivir
drug
sever
compound
known
inhibit
retroviru
enzym
implic
chemotherapi
htlv
infect
unknown
present
possibl
need
vaccin
chemotherapi
norwalk
viru
relat
agent
unclear
coronavirus
group
eleven
pleomorph
posit
strand
rnacontain
envelop
virus
review
siddel
et
al
tyrrel
et
al
robb
bond
infect
human
anim
bird
tabl
human
strain
mainli
infect
respiratori
tract
confin
normal
ciliari
epithelium
trachea
nasal
mucosa
alveolar
cell
lung
coronavirion
pleomorph
nm
diamet
clubshap
surfac
project
nm
length
fig
thin
section
virion
envelop
may
visual
inner
outer
shell
separ
transluc
space
intern
ribonucleoprotein
rnp
compon
coronavirion
visual
long
strand
nm
diamet
helic
rnp
condens
coil
structur
vari
diamet
normal
nm
coronavirion
nucleocapsid
contain
nonglycosyl
protein
mw
protein
phosphoryl
purifi
murin
hepat
viru
mhv
virion
shown
contain
protein
kinas
activ
coronavirion
contain
two
major
envelop
protein
matrix
protein
transmembran
glyco
siddel
et
al
protein
glycosyl
region
protein
exterior
virion
envelop
mani
case
matrix
protein
differ
degre
glycosyl
incorpor
virion
second
corona
virion
envelop
protein
constitut
surfac
peplom
respons
elicit
neutral
antibodi
infect
thu
vital
incorpor
vaccin
schmidt
kenni
mani
case
differ
molecular
weight
form
protein
incorpor
virion
protein
acyl
complex
mannoserich
carbohydr
sidechain
nglycosyd
link
polypeptid
virion
grown
cell
treat
tunicamycin
lack
peplom
protein
unabl
attach
cell
initi
infect
indic
coronavirus
proteolyt
process
peplom
protein
occur
morphogenesi
may
involv
activ
function
virusinduc
cell
fusion
collin
et
al
coronaviru
genom
linear
molecul
singlestrand
rna
polyadenyl
infecti
genom
rna
mw
x
loh
x
loh
correspond
nucleotid
fig
tiresist
oligonucleotid
fingerprint
genom
rna
intracellular
viral
mrna
confirm
posit
polar
genom
indic
extens
sequenc
reiter
madg
siddel
et
al
regard
earli
event
viruscel
interact
patterson
macnaughton
shown
virion
initi
attach
whole
cell
surfac
rapidli
redistribut
away
cell
peripheri
energyrequir
process
reason
redistribut
unknown
krzytyniak
dupuy
shown
uptak
cell
rapid
temperaturedepend
uptak
relat
phagocyt
capac
cell
may
therefor
involv
mechan
receptormedi
endocytosi
report
viruscel
system
heleniu
et
al
see
chapter
exampl
essenti
featur
viru
genom
replic
express
coronaviru
inform
cell
mediat
multipl
subgenom
mrna
form
cotermin
nest
set
ii
far
known
mrna
direct
translat
one
protein
iii
size
translat
product
rna
correspond
approxim
code
potenti
sequenc
absent
next
smallest
rna
although
proven
featur
inabl
ribosom
initi
translat
intern
site
eukaryot
mrna
suggest
sequenc
mrna
depict
gene
b
c
etc
fig
translat
protein
strategi
mani
parallel
strategi
positivestrand
rna
virus
see
chapter
also
coronaviru
strategi
appear
flexibl
one
allow
control
viral
protein
synthesi
level
transcript
translat
addit
detail
see
stern
kennedi
gener
smallest
rna
encod
intracellular
nucleocapsid
polypeptid
next
smallest
encod
matrix
protein
polypeptid
vitro
glycosyl
counterpart
oocyt
third
major
intracellular
rna
encod
peplom
protein
core
vitro
cotransl
glycosyl
peplom
precursor
oocyt
translat
product
two
mhv
rna
identifi
correspond
intracellular
viral
polypeptid
respect
final
morphogen
studi
matur
coronavirus
reveal
viru
assembl
restrict
cytoplasm
progeni
virion
form
bud
process
membran
rough
endoplasm
reticulum
virion
acquir
lipid
envelop
cell
exclud
host
cell
protein
process
subsequ
transport
accumul
golgi
complex
smooth
wall
vesicl
absenc
bud
plasmalemma
beesley
hitchcock
ducatel
et
al
holm
et
al
massalski
et
al
precis
mechan
viru
releas
mani
virus
elucid
date
littl
work
carri
date
human
coronavirus
either
point
view
vaccin
develop
specif
antivir
approach
may
use
investig
futur
genet
clone
may
particularli
use
develop
inactiv
vaccin
sinc
viru
would
difficult
replic
purifi
larg
quantiti
convent
vaccin
